Map kinase modulators and uses thereof
AssigneesThe Trustees of Columbia University in the City of New York, Northwestern University
InventorsOttavio ARANCIO, Daniel Martin WATTERSON, Jeffrey Claude PELLETIER, Saktimayee Mitra ROY
Life of this patent
Estimating the term…
Abstract
The invention provides for novel MAP kinase inhibitors and compositions comprising the same. In some embodiments, the MAP kinase inhibitors are p38α MAP kinase inhibitors. The invention further provides for methods for treatment of diseases comprising administration of MAP kinase inhibitors or compositions comprising MAP kinase inhibitors. In some embodiments, the disease is Alzheimer's Disease, ALS, Huntington's Disease or Parkinson's Disease.
Claims5
A method of treating amyotrophic lateral sclerosis in a subject comprising administration of a therapeutically effective amount of a compound of formula (I), or a composition comprising a compound of formula (I),
- wherein
- X1 is N and X2 is CH, or X1 is CH and X2 is N;
- R1 is —N(R4)2, cyclopropyl, or R5-piperidin-4-yl;
- R2 is independently D or halogen;
- R3 is naphthyl, quinolinyl, or isoquinolinyl, wherein said naphthyl, quinolinyl, or isoquinolinyl is optionally independently substituted with at least one D, halogen, (C1-C3)-alkoxy, or (C1-C3)-alkoxy substituted with at least one D;
- R4 is independently H, (C1-C4)-alkyl, (C1-C4)-alkyl substituted with at least one D, (C3-C5)-cycloalkyl, or each R4 together with the nitrogen to which they are attached form a 3-7 membered heterocyclic ring, wherein one of the carbon atoms is optionally replaced with NR6, O or S, and wherein the 3-7 membered heterocyclic ring is optionally substituted with a (C1-C3)-alkyl;
- R5 is H or (C1-C3)-alkyl, or (C1-C3)-alkyl substituted with at least one D;
- R6 is H, (C1-C3)-alkyl, (C1-C3)-alkyl substituted with at least one D, or pyrimidin-2-yl;
- and
- n is an integer from 0-4;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.